Immunotherapeutic effects of CpG oligodeoxynucleotide on murine transitional cell carcinoma

Objective To investigate the immunotherapeutic effects of CpG oligodeoxynucleotide(CpG-ODN)on murine transitional cell carcinoma.Methods After the BTT739 bladder tumor model in 24 T739 mice was successfully established,CpG-ODN and phosphate buffered saline were injected respectively into the margins of the tumor(peritumoral)on day 7 and day 14 after tumor cells inoculation.Tumor weight,volume,and the life span of mice were recorded.IL-12 level in serum was assessed by ELISA.The expression levels of CD80 and CD86 on TIDC of tumor tissues were detected by flow cytometry.Results Seven days after the second injection,average tumor weight was(3.30±0.81)g and(4.50±0.47)g respectively in the CpG-ODN group and the control group(P0.01).Average tumor volume was(3.57±0.84)cm3 and(4.84±0.58)cm3 respectively in the CpG-ODN group and the control group(P0.01).The life span of mice in the CpG-ODN group was significantly longer than that in the control group(P0.05).The level of IL-12 was(391.5±28.4)pg/mL and(257.2±13.7)pg/mL respectively in the CpG-ODN group and the control group(P0.01).The expression levels of CD80 on TIDC was 17.75%±3.13% and 11.32%±1.18% respectively in the CpG-ODN treatment group and the control group(P0.01).The expression level of CD86 on TIDC was 18.72%±2.79% and 12.65%±1.22% respectively in the CpG-ODN treatment group and the control group(P0.01).Conclusion CpG-ODN can inhibit tumor growth and prolong the living time of T739 mice with BTT739 bladder tumor via inducing the maturation of DC and promoting the secretion of Th1 cytokine IL-12 which polarize immune response to Th1 cells.